BLAINJECTIONINJECTABLE
Approved
Aug 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
72
Data completeness
4/8 — Partial
REPATHA (evolocumab) by Amgen is pcsk9 inhibitors [moa]. First approved in 2015.
Drug data last refreshed 2h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REPATHA (evolocumab) is a monoclonal antibody PCSK9 inhibitor administered by injection that lowers LDL cholesterol by blocking proprotein convertase subtilisin/kexin type 9, enabling increased hepatic LDL receptor activity. It is indicated for hypercholesterolemia, familial hypercholesterolemia, atherosclerotic cardiovascular disease, and acute coronary syndrome. The drug represents a paradigm shift in lipid management, offering significant LDL reduction beyond traditional statins for high-risk patients.
Peak
REPATHA remains in peak revenue phase with established market presence; commercial teams are stable and focused on market penetration and patient access optimization.
Mechanism of Action
PCSK9 Inhibitors
Pharmacologic Class:
PCSK9 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (72)
Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
Started Dec 2026
44 enrolled
Abdominal Aortic Aneurysm
A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
Started Apr 2026
5,995 enrolled
Cardiovascular DiseasesAtherosclerotic Cardiovascular DiseaseHypercholesterolemia, Familial
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
Started Apr 2026
400 enrolled
Healthy Participants
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
Started Jan 2026
400 enrolled
Healthy ParticipantsPharmacokinetics
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Started Dec 2024
69 enrolled
Dyslipidemias
Worked on REPATHA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.